Lantern PharmaLTRN
About: Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Employees: 24
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
800% more call options, than puts
Call options by funds: $108K | Put options by funds: $12K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
6% more funds holding
Funds holding: 31 [Q1] → 33 (+2) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1.68% less ownership
Funds ownership: 22.46% [Q1] → 20.78% (-1.68%) [Q2]
18% less capital invested
Capital invested by funds: $8.59M [Q1] → $7.08M (-$1.51M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for LTRN.
Financial journalist opinion
Based on 5 articles about LTRN published over the past 30 days









